Preclinical Investigations of a Novel PEGylated Long-Acting Human Growth Hormone.

Drug Des Devel Ther · 2025 · PMC12049125 · PMID 40322033

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

ZHB111 exhibited a significant dose-dependent variation in serum half-life in monkeys, with a decreasing trend as the dosage increased, ranging from 110 to 30 h, which was considerably longer than that of native hGH (3.4 h after SC injection in humans).

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.